+44 20 8123 2220
info@marketpublishers.com

SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

https://marketpublishers.com/r/S514AD8C6670EN.html
Date: July 2024
Pages: 159
Price: US$ 5,950.00 (Single User License)
ID: S514AD8C6670EN

Abstracts

This report can be delivered to the clients within 3 Business Days

SGLT2 Inhibitors Market Growth & Trends

The global SGLT2 inhibitors market size is anticipated t%li%reach USD 29.43 billion by 2030 and is expected t%li%expand at a CAGR of 7.71% during the forecast period, according t%li%a new report by Grand View Research, Inc. The recommendations and supportive guidelines from major health organizations, such as the American Diabetes Association (ADA), the European Association of for the Study of Diabetes (EASD), the European Society of Cardiology (ESC), and others have endorsed sodium-glucose cotransporter-2 (SGLT2) inhibitors for them beyond glucose control. For instance, in August 2023, the European Society of Cardiology (ESC) has issued a focused update t%li%their heart failure guidelines, integrating findings from nearly a dozen new clinical trials since 2021, such as EMPEROR-Preserved, DELIVER, STRONG-HF, and IRONMAN. Released at the ESC Congress 2023, the updated guidelines introduce new recommendations for the use of SGLT2 inhibitors in treating patients with heart failure with mildly reduced ejection fraction (HFmrEF).

In addition, the growing number of patients needing dialysis over the next few years showcased high demand of medicines such as SGLT2 inhibitors for treatment of CKD patients. In November 2023, the National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of empagliflozin, an SGLT2 inhibitor, for patients with chronic kidney disease (CKD). Empagliflozin has demonstrated efficacy in slowing the progression t%li%kidney failure and reducing the risk of heart attacks and strokes. NICE recommends making this treatment available t%li%patients across all stages of CKD. Such recommendations from drug regulatory agencies are expected t%li%boost demand for drugs during the forecast period.

The elder adults are more prone t%li%type 2 diabetes and heart failure, conditions where drugs have shown substantial benefits. This demographic shift increases the demand for effective treatments such as SGLT2 inhibitors. SGLT2 inhibitors are beneficial in reducing cardiovascular and renal risks, which are particularly prevalent in the elderly. This advantage makes these medications a preferred choice for older patients. According t%li%the World Health Organization (WHO), in 2022, around 1.4 billion people were aged 60 years and over, which was raised from 1 billion in 2020. In addition, WHO estimates that the elderly population is expected t%li%reach 2.1 billion. Thus, rising geriatric population is expected t%li%boost demand for SGLT2 inhibitors worldwide and drive market growth.

Increasing awareness of diabetes and significance of SGLT2 inhibitors in treatment among both patients and healthcare providers contribute t%li%higher prescription rates. For instance, in 2021, the WHO launched initiative “Global Diabetes Compact” t%li%raise awareness and improve patient access t%li%diabetic medicine including SGLT2 inhibitors and insulin. Such initiatives are expected t%li%boost adoption of SGLT2 inhibitors and open new opportunities in the market over the forecast period.

SGLT2 Inhibitors Market Report Highlights

Jardiance (empagliflozin) segment dominated the market in 2023 and is anticipated t%li%grow significantly over the forecast period. This growth is attributed due t%li%increasing prevalence of diabetes, CKD, and cardiovascular conditions and high drug demand for treatment

Type 2 diabetes segment dominated the market in 2023. This dominance is attributed due t%li%rising incidence of diabetes, increasing geriatric population, and increased prescription rate of drug

Hospital pharmacies segment dominated the market in 2023. This dominance is attributed due t%li%increasing number hospitalization of diabetes, CKD, and heart failure patients for diagnosis and treatment

+44 20 8123 2220
info@marketpublishers.com

North America dominated the market owing t%li%factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

+44 20 8123 2220
info@marketpublishers.com

Contents

CHAPTER 3. SGLT2 INHIBITORS MARKET VARIABLES, TRENDS & SCOPE

CHAPTER 4. SGLT2 INHIBITORS MARKET: DRUG ESTIMATES & TREND ANALYSIS

+44 20 8123 2220
info@marketpublishers.com

CHAPTER 8. COMPETITIVE LANDSCAPE

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

I would like to order

Product name: SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Product link: https://marketpublishers.com/r/S514AD8C6670EN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/S514AD8C6670EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature ____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970